News (2020)

Archive:
  • Archives

  • PRESS RELEASE – Dr. Daniel L. Vasella elected as new member of the Board of Directors of TOPADUR

    03.07.2020 / Media

    Zurich-Schlieren, Switzerland, July 1, 2020.  The shareholders of the company elected today Dr. Daniel L. Vasella, – former CEO and President of NOVARTIS – as new member to the Board of Directors of Topadur Pharma AG. “I am extremely happy with the election of Dr. Vasella to the Board of Directors. His visionary leadership and […]

    read more

    Teaser Video for swisstech.Bio 2020

    09.06.2020 / Media

    REPRESENTING SWITZERLAND ! Swisstech.Bio Digital presents the Swiss team selected for this years BIO Digital conference. Dr. Reto Näf representing TOPADUR in this online event from June  8 until June 12, 2020. The event is coordinated by the Swiss Embassy in New York under the lead of Innosuisse. Good luck to everybody ! Swisstech.Bio Digital […]

    read more

    TOPADUR under the eleven Swiss start-ups on the virtual BIO Digital stage !

    28.05.2020 / Media

    Even in the absence of physical presence, trade fairs are taking place in new formats. One of such events is the International Convention BIO, which turned into Bio Digital. At the upcoming online event from 8 -12 June 2020, more than 2300 companies from all over the world and start-ups will attend to learn and […]

    read more

    Scientific Publication in the Journal of Investigative Dermatology

    20.05.2020 / Media

    May 20, 2020 We are happy to announce that on May 18, 2020, under the title “A dual-acting nitric oxide donor and phosphodiesterase 5 inhibitor promotes wound healing in normal and diabetic mice” (JID-2019-0913.R1) the Journal of Investigative Dermatology accepted a manuscript for publication as confirmed by their Principal Deputy Director Thomas Krieg, MD. ABSTRACT […]

    read more

    TOPADUR Pharma Germany GmbH founded.

    20.05.2020 / Media

    For our first clinical trial in the EU, TOPADUR Pharma Germany GmbH, located at Georges-Köhler-Str. 2 in Lörrach, Germany, was entered in the company register in May 2020. Dr. Reto Näf and Dr. Christian Ludin act as our managing directors.

    read more

    Clinical Trial Application (CTA) documents filed – another significant TOPADUR milestone to our first clinical study !

    20.05.2020 / Media

    Dear TOPADUR followers, We are proud to announce that another important milestone of our dynamic young start-up was achieved on May 11, 2020. The application documents (Clinical Trial Application – CTA) for approval of our phase 1 study for diabetic foot ulcer (DFU) have been submitted to the authorities and the ethics committee.

    read more

    TOPADUR mentioned in Innosuisse Annual Report 2019

    08.05.2020 / Media

    Glaucoma is the second most common cause of blindness after cataracts, with over 100,000 people suffering from glaucoma in Switzerland and over 64 million people worldwide.  With its latest research, TOPADUR, with the support of Innosuisse and in collaboration with the University of Zurich and the Institute for Molecular and Clinical Ophthalmology of the University […]

    read more